eribulin
Selected indexed studies
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. (Lancet, 2016) [PMID:26874885]
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. (Lancet, 2011) [PMID:21376385]
- Eribulin. (Drugs, 2011) [PMID:21770478]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. (2016) pubmed
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. (2011) pubmed
- Eribulin. (2011) pubmed
- Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. (2015) pubmed
- Eribulin in advanced liposarcoma and leiomyosarcoma. (2017) pubmed
- Clinical and preclinical features of eribulin-related peripheral neuropathy. (2022) pubmed
- Eribulin mesylate. (2011) pubmed
- Eribulin in non-small cell lung cancer: challenges and potential strategies. (2017) pubmed
- Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. (2015) pubmed
- Eribulin-based treatment in patients affected by sarcomas: a case series. (2020) pubmed